Ginkgo Bioworks Holdings, Inc. (DNA) is a publicly traded Healthcare sector company. As of July 5, 2026, DNA trades at $10.40 with a market cap of $679.37M and a P/E ratio of -1.94. DNA moved -0.10% today. Year to date, DNA is +27.61%; over the trailing twelve months it is -17.85%. Its 52-week range spans $5.00 to $17.58. Analyst consensus is neutral with an average price target of $12.00. Rallies surfaces DNA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Ginkgo Bioworks Unveils ADME-One Platform Featuring Five Tier 1 Assays and AI PK Projections: Ginkgo Bioworks launched ADME-One, a fully integrated high-throughput ADME platform co-developed with Tangible Scientific and Inductive Bio, offering five Tier 1 assays and AI-driven human PK projections. The U.S.-based workflow delivers turnkey compound management and standardized data at a price several times lower than industry offshore alternatives.
| Metric | Value |
|---|---|
| Price | $10.40 |
| Market Cap | $679.37M |
| P/E Ratio | -1.94 |
| EPS | $-5.36 |
| Dividend Yield | 0.00% |
| 52-Week High | $17.58 |
| 52-Week Low | $5.00 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $141.31M |
| Net Income | $-304.39M |
| Gross Margin | 0.00% |
2 analysts cover DNA: 0 strong buy, 1 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $12.00.